[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100565975":3},{"organization":4,"outcomesModule":7,"designInfo":13,"detailedDescription":11,"studyPopulation":16,"armGroups":11,"interventions":11,"overallOfficials":11,"centralContacts":17,"locations":23,"responsibleParty":52,"collaborators":11,"id":54,"slug":11,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":11,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":61,"maxAge":11,"enrollmentInfo":62,"targetDuration":11,"studyType":65,"phases":11,"briefSummary":66,"conditions":67,"keywords":11,"overallStatus":26,"whyStopped":11,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"Boryung Pharmaceutical Co., Ltd","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":11,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Percentage of subjects who correspond to high risk score (≥8) by evaluating simple NAFLD score",null,"Baseline (visit 1)",{"allocation":11,"interventionModel":11,"interventionModelDescription":11,"primaryPurpose":11,"observationalModel":14,"timePerspective":15,"maskingInfo":11},"COHORT","PROSPECTIVE","Patients with type 2 diabetes scheduled to administer a fixed-dose combination of dapagliflozin\u002Fpioglitazone",[18],{"name":19,"role":20,"phone":21,"phoneExt":11,"email":22},"Shin-young Oh","CONTACT","+82-2-708-8000","syoh@boryung.co.kr",[24,40],{"facility":25,"status":26,"city":27,"state":28,"zip":29,"country":30,"countryCode":11,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"Andong Hospital","RECRUITING","Andong","Gyeongsangbuk-do","36743","South Korea",{"type":32,"coordinates":33},"Point",[34,35],128.72275,36.56636,{"lat":35,"lon":34},[38],{"name":39,"role":20,"phone":11,"phoneExt":11,"email":11},"Joong-kyung Sung",{"facility":41,"status":42,"city":43,"state":11,"zip":11,"country":30,"countryCode":11,"cosmosGeoPoint":44,"geoPoint":48,"contacts":49},"Konkuk University medical center","NOT_YET_RECRUITING","Seoul",{"type":32,"coordinates":45},[46,47],126.9784,37.566,{"lat":47,"lon":46},[50],{"name":51,"role":20,"phone":11,"phoneExt":11,"email":11},"Kee-ho Song",{"type":53,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100565975",false,"NCT06649162","A Study to Identify the Risk of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients With Type 2 Diabetes in Clinical Practice and to Evaluate the Clinical Usefulness of Dapagliflozin\u002FPioglitazone Combination Therapy","A Multi-center, Prospective, Cohort Study to Identify the Risk of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients With Type 2 Diabetes in Clinical Practice and to Evaluate the Clinical Usefulness of Dapagliflozin\u002FPioglitazone Combination Therapy","Inclusion Criteria:\n\n* Among patients with type 2 diabetes, those who are scheduled to administer a fixed-dose combination of dapagliflozin\u002Fpioglitazone at baseline (visit 1)\n* Those who voluntarily signed a written personal information collection and usage agreement after listening to an explanation about the objective and method, etc. of this clinical study.\n\nExclusion Criteria:\n\n* Those who have a history of taking a fixed-dose combination of dapagliflozin\u002Fpioglitazone at baseline (visit 1).\n* Those who are expected to need insulin prescription during the study period.","ALL","19 Years",{"count":63,"type":64},10000,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to identify the risk of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes in clinical practice and to evaluate the clinical usefulness of Dapagliflozin\u002FPioglitazone combination therapy",[68],"Type 2 Diabetes","2024-10-17",{"date":71,"type":72},"2024-10-18","ACTUAL",{"date":74,"type":72},"2024-09-30",{"date":76,"type":64},"2027-03",{"name":5,"class":6},2]